GLIA Diagnostics
Making the Invisible Injury Visible.
From Diagnosis to Recovery. Beyond Detection to Better Care.
GLIA Diagnostics is an Australian medtech company translating clinically studied microRNA biomarkers into a rapid, portable point-of-care platform for traumatic brain injury. Our research investigates molecular signals associated with acute injury, prognosis and recovery, with the objective of providing complementary biological information alongside established clinical assessment.
Investigational technology in development. Not approved for commercial clinical use.
5
Human research studies and cohorts
4
Peer-reviewed human clinical publications
7-miRNA
Biomarker research portfolio
Industry Replication
Core CSIRO electrochemical outcomes reproduced
Research metrics subject to final verification. All figures relate to investigational research. The platform is not approved for commercial clinical use.
Who We Are
About GLIA Diagnostics
GLIA Diagnostics is an Australian medtech company developing a platform intended to provide objective biological information following traumatic brain injury (TBI), including mild TBI and concussion. Its clinically studied multiplex microRNA biomarker programme is being translated toward a portable point-of-care platform. The intended system combines a biological sample, a disposable cartridge and a handheld reader, with a rapid result time as a development target. GLIA is currently progressing integrated product engineering, analytical characterisation and regulatory planning.
The problem
Brain injury is not always visible.
Concussion and mild traumatic brain injury can occur without obvious structural abnormalities on conventional imaging. Clinical assessment continues to rely heavily on symptoms, examination and cognitive testing. GLIA is developing a complementary source of objective biological information to support clinical decision-making.
The GLIA approach
Looking at the biology of brain injury.
01
microRNA biology
GLIA's approach uses circulating microRNAs — small regulatory molecules involved in biological responses to injury — as the basis for its biomarker programme.
02
Human clinical research
Our biomarker research has identified a panel of microRNAs associated with traumatic brain injury across civilian, sporting and military research cohorts, with findings published in peer-reviewed journals.
03
Point-of-care translation
GLIA is translating this biomarker science into a portable electrochemical point-of-care platform designed for rapid testing from a small blood sample, targeting use closer to the patient.
Point-of-care technology
From biomarker discovery to point-of-care testing.
GLIA is translating its microRNA biomarker research into a portable electrochemical point-of-care platform designed for rapid testing from a small blood sample.
The development objective is to enable biological information to move closer to the patient, athlete or operator — rather than requiring conventional central laboratory testing. A rapid result time is a target of the development programme.
Technology Transfer
Successful Transfer From Research to Industry-Based Development
Following completion of the CSIRO development programme, GLIA transferred the sensor preparation, assay chemistry and electrochemical workflow into a separate industry-based development environment at Memjet. The core experimental outcomes documented in CSIRO's final product-development report were successfully reproduced in the new setting.
This provides important evidence of reproducibility and successful technology transfer beyond the originating controlled research environment, materially reducing translation risk as GLIA progresses toward integrated product engineering and analytical validation.
Development progression
Why it matters
The case for objective biological information.
Complementary biological information at the point of need
Current TBI assessment relies on clinical observation, imaging and cognitive testing. GLIA is developing a complementary source of objective biological information that can be used closer to the patient — not as a replacement for established clinical assessment.
Rapid result — a development target
The intended platform targets a rapid sample-to-result time without laboratory infrastructure. This remains a development objective, not a validated clinical specification.
Multiplex miRNA panel
A multi-marker miRNA panel rather than a single-biomarker approach, reflecting the biological complexity of traumatic brain injury.
Our Technology
Grounded in Rigorous Molecular Science
Multiplex miRNA Biomarker Programme
GLIA is investigating a circulating miRNA panel supported by human research across acute TBI, mild TBI and longitudinal recovery. The programme is being developed as a complementary molecular approach to brain-injury assessment, with findings published in peer-reviewed journals.
PoC Platform Development
GLIA is translating its clinically studied biomarker programme toward a portable PoC system intended to bring objective molecular information closer to the patient. Device representations on this site are conceptual illustrations of technology under development.
Regulatory Pathway
GLIA is progressing regulatory planning for major international markets, including Australia, the United States and Europe. The final intended use and regulatory pathway remain subject to regulatory engagement and product validation. No regulatory clearance or approval has been obtained.
Evidence
Built on human clinical research.
GLIA's microRNA biomarker programme has been evaluated across multiple human studies involving traumatic brain injury, concussion, sport and military populations. The research programme includes four peer-reviewed publications and ongoing translational studies. All performance and diagnostic claims are investigational.
View Clinical EvidenceHuman evidence base
Five human studies and cohorts across acute injury, mild TBI, recovery and related settings — subject to final verification of counting methodology.
4 peer-reviewed publications
Published human research investigating TBI-associated circulating miRNA signals, longitudinal biology and recovery.
Multi-marker miRNA panel
A multiplex circulating miRNA panel selected through GLIA's research and IP programme, investigating injury, prognosis and recovery signals.
Development Roadmap
Advancing From Research to PoC
Clinical Foundation
Human biomarker research, clinical cohorts, peer-reviewed publications and intellectual property established.
CSIRO Development
Electrochemical miRNA sensing platform developed and characterised through the CSIRO development programme.
Industry-Based Replication
Core experimental outcomes documented in CSIRO's final development report successfully reproduced at Memjet in a separate industry-based development environment.
Integrated Product Engineering
Integration of assay chemistry, disposable cartridge, electronics and reader toward the intended portable point-of-care system. Includes analytical reproducibility, sensor stability and progression toward the broader miRNA panel.
Analytical, Clinical & Regulatory Validation
Integrated whole-blood product qualification, prospective clinical validation, regulatory engagement and commercialisation preparation.
Commercial Milestones
Progress From Research to Product Translation
Founded 2015
Human clinical evidence established
Four peer-reviewed human publications
International IP portfolio
CSIRO electrochemical PoC development completed
Industry-based replication achieved
Integrated product engineering underway
Regulatory planning in progress
Competitive Advantage
A Differentiated Position in TBI Diagnostics
GLIA's miRNA approach is complementary to existing clinical assessment and approved TBI diagnostic technologies, including established protein-biomarker testing. GLIA combines a clinically studied multiplex miRNA biomarker programme, an international intellectual property portfolio and proprietary point-of-care technology. Successful reproduction of the CSIRO development outcomes in an industry-based environment provides additional evidence that the underlying sensing technology is transferable beyond its originating research setting.
Clinically Studied Biomarker Programme
Five human studies and cohorts across acute TBI, mild TBI, sport and military populations, with four peer-reviewed publications. Investigational — not approved for clinical use.
International IP Portfolio
Intellectual property covering the miRNA biomarker panel and point-of-care platform, filed across key international markets. Includes both licensed foundational IP and GLIA-owned platform IP.
Proprietary PoC Technology
Electrochemical miRNA sensing platform developed through the CSIRO programme and successfully reproduced in an industry-based environment at Memjet.
Demonstrated Technology Transfer
Successful reproduction of CSIRO development outcomes at Memjet provides evidence of transferability beyond the originating controlled research environment, reducing translation risk.
Intellectual Property
International IP Portfolio
GLIA holds an international intellectual property portfolio covering its microRNA biomarker panel and point-of-care platform technology. The portfolio includes both licensed foundational biomarker IP and GLIA-owned or assigned electrochemical platform IP.
miRNA Biomarker Panel
Filed internationallyElectrochemical Detection Platform
Filed internationallyPoint-of-Care System Architecture
Filed internationallyIP status is subject to ongoing prosecution. Patent applications and granted patents are distinguished within the portfolio. Details are commercially sensitive.
Competitive Landscape
Where GLIA Sits in the TBI Diagnostics Space
Current TBI assessment relies on clinical observation, imaging and neurocognitive testing. Approved protein-biomarker tests — including Abbott's FDA-cleared acute TBI diagnostic systems using GFAP and UCH-L1 — are available for specific indications. GLIA's miRNA approach is complementary and investigational, not a replacement for established clinical assessment or approved diagnostics.
Imaging
CT and MRI provide structural information but may not detect mild TBI. Require specialist infrastructure and are not suited to point-of-care use.
Protein Biomarkers
Protein-based blood biomarkers (GFAP, UCH-L1) have received regulatory clearance in some markets for specific acute TBI indications. GLIA's miRNA approach investigates complementary and potentially distinct biological signals.
Neurocognitive Testing
Standardised cognitive assessments are widely used but are subjective and can be confounded by baseline variation, effort and learning effects.
The GLIA Difference
What Sets GLIA Apart
Multiplex miRNA panel — investigating injury, prognosis and recovery signals, not a single-marker approach
Human clinical evidence across sport, military and civilian cohorts, with four peer-reviewed publications
Electrochemical PoC platform developed through CSIRO and reproduced at Memjet in an industry-based environment
International IP portfolio covering both the biomarker panel and the point-of-care platform technology
Demonstrated technology transfer beyond the originating controlled research environment
Progressing integrated product engineering toward an engineered, scalable diagnostic product
Research, Development & Engagement Network
Built Through Collaboration
CSIRO — Completed electrochemical platform development programme
Memjet — Industry-based technology replication and development environment
Genesys Electronics Design — Integrated electronics, reader and product engineering
The Alfred Hospital — Clinical research partner
Monash University — Academic research collaboration
Defence Science and Technology Group — Military TBI research engagement
Where it matters
Designed for the settings where TBI occurs.
Elite Sport
Rapid biological information at the point of injury to support clinical decision-making in professional and elite sport settings.
Defence
Objective biological assessment for military personnel exposed to blast overpressure and combat-related TBI.
Emergency & Clinical
Complementary biological information for emergency department and clinical assessment of TBI and concussion.
Grassroots Sport
Accessible point-of-care testing to support concussion assessment at community and grassroots sport levels.
Collaboration & Investment
Building through collaboration.
GLIA has progressed from biomarker discovery and human clinical evidence through electrochemical proof of concept, CSIRO development and successful industry-based replication. The programme is now advancing into integrated product engineering, analytical characterisation and regulatory preparation. GLIA welcomes informed scientific and strategic conversations with diagnostic industry partners, investors, clinicians, research collaborators, defence stakeholders and sporting organisations.
Partners & CollaboratorsGLIA Diagnostics
Objective biology for traumatic brain injury.
An overview of the GLIA Diagnostics platform and its intended application.
References
- 1.
Mitra B et al. Plasma micro-RNA biomarkers for diagnosis and prognosis after traumatic brain injury: A pilot study. J Clin Neuroscience. 2017. DOI: 10.1016/j.jocn.2016.12.009
- 2.
Mitra B et al. Micro-RNA levels and symptom profile after mild traumatic brain injury: A longitudinal cohort study. J Clin Neuroscience. 2022. DOI: 10.1016/j.jocn.2021.11.021
- 3.
Mitra B et al. MicroRNA biomarkers for diagnosis of mild traumatic brain injury and prediction of persistent symptoms: A prospective cohort study. J Clin Neuroscience. 2023. DOI: 10.1016/j.jocn.2023.07.011
- 4.
Mitra B et al. MicroRNA Biomarkers on Day of Injury Among Patients with Post Concussive Symptoms at 28-Days: A Prospective Cohort Study. MicroRNA. 2024;13(3):233–239. DOI: 10.2174/0122115366297817240613065052
Stay informed.
Subscribe for updates on GLIA's research and development programme.
Contact
Get in touch.
GLIA Diagnostics
Mosman, Sydney NSW 2088, Australia